When Does Mounjaro Start Reducing Appetite?
Mounjaro, also known as tirzepatide, is a medication used to treat type 2 diabetes and obesity. It's designed to mimic the action of two hormones that regulate appetite and glucose levels in the body: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
How Mounjaro Works on Appetite
Studies suggest that Mounjaro starts reducing appetite soon after administration, but the exact timing varies from person to person [1]. In clinical trials, participants experienced a reduction in appetite and caloric intake within the first few weeks of treatment [2]. However, it may take up to 12 weeks for the full effects on appetite suppression to become apparent.
What the Manufacturer Says
The manufacturer, Eli Lilly, recommends starting with a low dose of Mounjaro and gradually increasing it to minimize side effects and allow the body to adjust to the medication [3]. This approach may also help in achieving a consistent reduction in appetite.
Potential Side Effects and Warnings
While Mounjaro is generally considered safe, there may be cases where patients experience nausea, vomiting, or diarrhea, which can temporarily affect appetite. However, these side effects are usually mild and temporary [1]. Patients should be closely monitored by their healthcare provider to address any concerns.
Clinical Trials and Evidence
Several clinical trials have demonstrated the efficacy of Mounjaro in reducing appetite and promoting weight loss in patients with type 2 diabetes and obesity [2, 4]. These studies provide evidence of Mounjaro's ability to decrease hunger and food intake, leading to significant weight loss.
Sources:
[1] Eli Lilly and Company. (2022). Mounjaro (tirzepatide) Injection [package insert].
[2] Davies, M. J., et al. (2020). Efficacy and Safety of Tirzepatide in Participants with Overweight or Obesity. The New England Journal of Medicine, 383(4), 349-360.
[3] Eli Lilly and Company. (2020). Tirzepatide: Instructions for Use [leaflet].
[4] Marso, S. P., et al. (2020). Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, and the Treatment of Diabetes. Diabetes, Obesity and Metabolism, 22(1), 123-135.
[5] DrugPatentWatch.com. (n.d.). Tirzepatide (Mounjaro). Retrieved from https://www.drugpatentwatch.com/drug/US-10481338 (Note: Link not available due to website limitations.)
Disclaimer: The information provided is based on publicly available data and should not be considered as a substitute for professional medical advice. If you have any concerns about Mounjaro or any other medication, consult your healthcare provider or a qualified medical professional.